Drug Profile
Research programme: antifungals - Eli Lilly and Company
Alternative Names: Antifungals research programme - Eli Lilly and CompanyLatest Information Update: 01 Aug 2002
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Cyclic peptides
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 11 Sep 2000 Preclinical development for Mycoses in USA (Unknown route)